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Introduction: Six out of every 10 elderly persons live in developing countries.
Objective:  To analyze and assess the drug prescription patterns and errors in elderly outpatients 
attending public health care centers in Mexico City, Mexico.
Materials and methods: A descriptive and retrospective study was conducted in 2007. 
Fourteen hundred prescriptions were analyzed. Prescriptions of ambulatory adults aged 70 years 
who were residents of Mexico City for at least two years were included. Prescription errors were 
divided into two groups: (1) administrative and legal, and (2) pharmacotherapeutic. In group 2, 
we analyzed drug dose strength, administration route, frequency of drug administration, treatment 
length, potential drug–drug interactions, and contraindications. Variables were classified as 
correct or incorrect based on clinical literature. Variables for each drug were dichotomized 
as correct (0) or incorrect (1). A Prescription Index (PI) was calculated by considering 
each drug on the prescription. SPSS statistical software was used to process the collected data 
(95% confidence interval; p  0.05).
Results: The drug prescription pattern in elderly outpatients shows that 12 drugs account for 
70.72% (2880) of prescribed drugs. The most prescribed drugs presented potential pharmacothera-
peutic errors (as defined in the present study). Acetylsalicylic acid–captopril was the most common 
potential interaction (not clinically assessed). Potential prescription error was high (53% of total 
prescriptions). Most of the prescription errors were due to omissions of dosage, administration 
route, and length of treatment and may potentially cause harm to the elderly outpatients.
Conclusions: A high number of potential prescription errors were found, mainly due to omis-
sions. The drug prescription pattern of the study population is mainly constituted by 12 drugs. 
The results indicate that prescription quality depends on the number of prescribed drugs per 
prescription (p  0.000).
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Introduction
Globally, the number of persons aged 60 years or over is expected almost to triple, 
increasing from 672 million in 2005 to nearly 1.9 billion by 2050.
In developed countries, 20% of the population is aged 60 years or over and is 
projected to be 32% by 2050. In the developing world, the proportion of the population 
aged 60 or over is expected to rise from 8% in 2005 to close to 20% by 2050.1
In Mexico (a middle income country), in 2004 it was estimated that the population 
aged 60 years or over would reach 7.9 million, representing 7.5% of the total popula-
tion and 3.5 million of them would be aged 70 years or over. In 2010, the elderly will 
number 9.9 million (8.9% of the whole population), 15 million (12.5%) in 2020, and 
more than 22 million (17.5%) in 2030.2Clinical Interventions in Aging 2009:4 344
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The main causes of death in the elderly population 
in  Mexico  are  cardiovascular  diseases  (28.6%), 
chronic-degenerative diseases such as malignant tumors 
and cerebrovascular diseases (15.5%), and diabetes mellitus 
(11.6%). Inappropriate medication use is a major patient 
safety concern, especially for the elderly population.3,4 
Prescription of medicines is a fundamental component of the 
health care of elderly people, and optimization of prescribing 
for this group of patients has become an important public 
health issue worldwide.5
The higher incidence of chronic diseases and degenera-
tive pathologies increases demand for prescription medi-
cines to treat these conditions, alleviate pain, and provide 
quality of life and well-being, which renders older adults 
susceptible to the risk of polypharmacy and drug-related 
illnesses.5–7
In Brazil, the frequency of drugs used has been observed 
in metropolitan areas, with a mean utilization ranging 
from two to five medications per day, and one third of all 
elderly take more than five medications simultaneously.6 
Consequently, elderly patients are at high risk of drug–drug 
interactions and drug-adverse events that are generally 
preventable.7–10
Gurwitz and colleagues reported that 13% of preventable 
prescribing errors detected in ambulatory patients involved 
drug–drug interactions.8
Elderly people consume more medicines than the general 
population and this trend increases with age, which increases 
the probability of interactions among several medicines and 
consequently a major number of adverse effects have been 
associated with disabling conditions.11–13
The inadequate and inappropriate use of medicines 
and prescription patterns raise unnecessarily the cost of 
health care.14–16 Appropriate use of medicines is of critical 
importance for achieving good health in patients and for 
effective and efficient use of health care resources.17
It has been documented that prescription errors that 
appear with major frequency are related to dosage, 
prescription of medicines to which the patient is allergic, or 
indication of an inadequate administration route.18
Medications are the most common form of therapy. 
However, irrational and therefore dangerous prescriptions 
represent a very high economic, social, and health impact 
on most countries.19
In Mexico, few studies exist on drug prescription 
patterns and errors in elderly people and even fewer in 
public primary health care centers or ambulatory health 
systems.
Need for research
As mentioned earlier, there are an increasing number of 
elderly patients, which create new health care challenges 
since they have special needs.
In 2001, a special public health care program was created 
in order to give universal health care coverage to the elderly 
population aged over 70 years, including drugs, laboratory 
tests, and all medical services.
Mexico has an Essential Drug List (EDL) and its 
use is compulsory for all public institutions (Ministry of 
Health, federal and state health care centers, “Mexican 
Social Security Instute” Instituto Mexicano del Seguro 
Social [IMSS] and “Social Services for State workers 
Institute” Instituto de Seguridad y Servicios Sociales de los 
Trabajadores del Estado [ISSSTE].20–22 The design of the 
Mexican EDL is based on the World Health Organization 
(WHO) concept of rational use of drugs: efficacy, safety 
and cost.23
Many questions arise regarding prescribing in elderly 
people included in the special public health care program 
mentioned above:
•  The kind of drugs being prescribed in the ambulatory 
health care system of the Ministry of Health of the Federal 
District (SSADF).
•  The drugs prescribed, considering the Mexican public 
health sector’s EDL.
•  The appropriateness of drug prescribed.
•  The frequency and type of prescription errors.
•  Potential drug–drug interactions and contraindications.
•  The quality level of the drug prescriptions in Mexico DF 
ambulatory health care system.
The specific goals of this work were (a) to describe drug 
patterns of use in elderly Mexican population and (b) to 
analyze the prescriptions to detect possible errors.
Methods
study setting
The Mexican health care system was initially formed with 
a component of public institutions in order to offer health 
care services to both the uninsured population, who are 
usually unsalaried with little economic power (Ministry 
of Health, or Secretaría de Salud [SSa], as well as the 
insured population, represented by salaried workers from 
the formal economic sector of the population (r IMSS, 
and ISSSTE). The other components of the health care 
system refer to the private sector, with a broad array of 
institutions offering health care services to the population 
with purchasing power.24Clinical Interventions in Aging 2009:4 345
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In the public health care system, all prescriptions should 
be written using only generic names (no brand names are 
allowed). In the primary health care system (health care 
centers belonging to Mexico City’s Ministry of Health), most 
of the physicians are general practitioners or without medical 
specialties (no geriatricians). A maximum of three drugs are 
allowed to be included in one single prescription, but two or 
more prescriptions can be used for one single patient. There is 
no limit for the total number of drugs to be prescribed to one 
single patient, but different prescription sheets must be used.
There are 210 health care centers of SSADF; 134 of them 
have a pharmacy. As mentioned earlier, the beneficiaries 
of those centers are the uninsured population, who are 
unsalaried with little economic power. There are about 2,213 
general physicians.
Inclusion criteria
Prescriptions of ambulatory adults aged 70 years or over (age 
was a criteria defined in the health care program analyzed in 
the present investigation), who were residents of Mexico City 
for at least two years, and were registered in a health care 
center of SSADF close to his/her residency. All prescriptions 
had to be issued during the study period (January to December 
2007). All the prescriptions issued during 2007 for elderly 
people (for the present study it was defined as elderly aged 
70 years or over) were included to calculate the sample size.25 
All prescriptions must include a prescription serial number, 
the name of the patient, age, home address, weight, gender, 
diagnosis, drugs (generic name and EDL code number), 
dose, dosage frequency, route of administration, duration of 
treatment, and patient and physician signatures.
exclusion criteria
All prescriptions that were illegible or not clearly written and 
did not meet the inclusion criteria were excluded.
sample size
The size of the sample was calculated using the formula for a 
population proportion taken into account the pilot test sample 
data which resulted in 1,400 prescriptions. Prescriptions were 
selected randomly.26,27
study design
A descriptive and retrospective study was conducted.
study variables
Continuous and categorical study variables
Among the continuous variables are the number of drugs 
prescribed per patient per prescription as a whole and age. 
Categorical variables are gender and diagnosis as written on 
the prescription.
In order to analyze prescription errors, we divided 
them into two groups: administrative and legal (group 1) 
and pharmacotherapeutic (group 2) errors. In group 1, 
we analyzed: 1) EDL code number (included by Mexican 
General Health Law), 2) physician’s signature, 3) physician 
identification number, 4) number of drugs included in 
the EDL, and 5) number of drugs prescribed using brand 
names.
Variables 1 to 5 were dichotomized as included in the 
prescription (0) and not included (1). When the total sum of all 
the administrative and legal variables was 0, the prescription 
was considered correct (variables 1 to 4) and incorrect when 
the sum was greater than 0 (variables 1 to 5).
In group 2, we analyzed drug-dose strength, administra-
tion route, frequency of drug administration, treatment 
length, drug–drug potential interactions, and contraindica-
tions. The variables were classified as correct or incorrect 
based on clinical literature.28–31 Variables were dichoto-
mized as correct (0) or incorrect (1). Inappropriate drug use 
was considered when the prescribed drug did not comply 
with EDL guidelines, Beer’s criteria, and the corresponding 
clinical literature.20,32–34 In other words, inappropriate drug 
use was when the selection of drug, the dose, route of 
administration, drug administration frequency, treatment, 
etc. did not match what is established or recommended in 
the clinical literature as an appropriate use of drug in the 
elderly.
Data collection
SPSS statistical software (version 13; SPSS Inc., Chicago, IL, 
USA) was used for processing the collected data. Univariate, 
bivariate, and logistic regression statistical analyses were 
performed. By using the univariate analysis, patient 
frequency was calculated with regard to the continuous and 
categorical variables described above.
Variables at the patient level
To assess the quality of the prescription by patient, the 
following variables were considered: 1) number of drugs 
prescribed per each patient, 2) diagnosis per prescription per 
patient, 3) age, and 4) gender.
According to the clinical literature on the subject, 
potential drug–drug interactions and contraindications were 
identified and quantified.35,36 The 12 most prescribed drugs 
for the 1,400 outpatients during the study period were chosen 
for this analysis.Clinical Interventions in Aging 2009:4 346
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Variables at the prescription level
Only variables of group 2 were considered to determine 
prescription quality. To determine prescription quality, 
a Prescription Index (PI) was calculated by considering 
each drug on the prescription. Clinical literature was 
used to revise each drug. The variables were: 1) drug, 
2) dose, 3) administration route, 4) dose frequency, 
5) treatment length, 6) potential drug–drug interactions, and 
7) contraindications. All these variables were dichotomized 
as correct/incorrect. The value intervals ranged between 
0 and 7. For the last two variables (potential drug–drug 
interactions and contraindications), when the prescribed 
drug aggravated the patient’s health status due to increasing 
drug toxicity, these effects were 1 when they were present 
in the prescription and 0 if they were absent.
The PI was calculated as the sum of the values assigned 
to each of the seven variables, which were divided into the 
total number of drugs per prescription. These values were cat-
egorized as 0 (good quality: without any errors) and greater 
than 0 up to 0.75 (regular), greater than 0.75 to 1.5 (bad), and 
greater than 1.5 (very bad). For any undesirable situation, the 
prescription quality is assumed as poor or incorrect.
The PI used was also based on what Baber defined in 
1995 as a good prescription, although Baber also included 
the drug cost and patient choice, which was not included in 
the present study.37
Bivariate and multivariate statistical analyses
The prescription quality rate (by drug and by patient) was 
compared with the following variables to establish an associa-
tion: 1) number of prescribed drugs, 2) age, and 3) gender. 
The Chi-squared test was used for categorical variables 
and the Student’s t-test or Mann–Whitney test was used to 
compare continuous variables. In every case, the relation of 
the variables with the PI was considered significant when 
p  0.05.
A logistical regression multivariate analysis was 
conducted with all the variables that proved significant in the 
bivariate analysis, both for the prescription quality index by 
drugs and by patient. Variables with p  0.05 were consid-
ered statistically significant.
Results
Results of the continuous and categorical 
variables of the study
A total of 1,400 prescriptions were analyzed, corresponding 
to 1,400 patients, of which 71% (996) were female and 29% 
(404) male. The total amount of patients (1,400) was divided 
into four age groups: 54% (760) patients were aged 70–75, 
29% (401) were aged 76–81, 13% (181) were aged 82–87 
and, 4% (58) were aged 88–99 years, respectively.
It was found that, of a total of 1,400 prescriptions, 61.4% 
(859) had one diagnosis, 32% (447) had two, and 6% (85) 
had three, and less than 1% had four or five diagnoses. The 
patients’ main diagnoses were: 28.5% (583) hypertension, 
14% (287) type 2 diabetes mellitus, 10% (204) pharyngitis, 
7% (139) rheumatoid arthritis, 6% (125) gastritis, 5% (101) 
urinary tract diseases, 3.2% (65) osteoarthritis, 2.3% (46) 
peripheral venous insufficiency, 2% (40) rhinitis, 2% (40) 
colitis, 2% (35) gastrointestinal infections, 2% (32) backache, 
and 18% (37) were other diagnoses each with less than 1% 
frequency (total diagnosis frequency was 2,045). Twelve 
diagnoses represented about 82% (2,045) of the total diag-
noses included in 1,400 prescriptions.
In order to determine drug prescription patterns in the 
study setting (ambulatory health care centers), the total 
prescribed medications (2,880 drugs) included in all the 
prescriptions (1,400) were analyzed: 36.6% (512) included 
two, 31.50% (441) three, 30.43% (426) one, 0.57% (4) four, 
0.36% (5) five, and 0.57% (8) six drugs, respectively.
In order to determine the drug prescription, the top 
12 drugs found in the total prescriptions (1,400) were: capto-
pril 16.07% (463 times), naproxen 10.34% (298), glyburide 
8.02% (231), trimethoprim/sulfamethoxazole 6.18% (178), 
ambroxol 4.89% (141), diclofenac 4.65% (134), ranitidine 
4.4% (126), acetaminophen 3.9% (112), metformin 3.71% 
(107), acetylsalicylic acid (ASA) 3.47% (100), B complex 
2.56% (74), and metoprolol 2.53% (73). Only 12 drugs rep-
resented 70.72% (2,037 drugs) of the total drugs prescribed 
(2,880) in 1,400 prescriptions.
The Mexican EDL has 24 therapeutic groups. All drugs 
prescribed (2,880) were classified and quantified by therapeu-
tic group. The major therapeutic groups were: cardiological 
diseases 22.7% (656), infectious diseases 17% (489), rheu-
matic diseases 15.5% (446), endocrinological diseases 13.3% 
(384), gastroenterological diseases 8.3% (218), and analgesic 
7.56% (218). Six of the therapeutic groups represented 84.3% 
of all the drugs prescribed in 1,400 prescriptions.
Administrative and legal errors found in the analyzed 
prescriptions (group 1)
The results of the prescription errors in the administrative and 
legal variables found were: 1) 95% (1,332 prescriptions) did 
not have the EDL code numbers, 2) 97% (1,359) prescriptions 
were found with physician’s signatures and without them 
3% (41), 3) 96% (1,348) prescriptions did not include the Clinical Interventions in Aging 2009:4 347
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physician’s identification number, and only 4% (52) of the total 
prescriptions had the physician’s identification number, 4) in 
99.99% (1,399) of prescriptions, the name of the active prin-
cipal (a constituent of a drug on which the characteristic thera-
peutic action of the substance largely depends) was included 
in the EDL and, only one active principal of one drug in one 
prescription was not included in the EDL, and 5) a total of 13 
drugs were written using brand names not generic ones.
Results of errors due to pharmacotherapeutic 
variables (group 2)
All 2,880 prescribed drugs were analyzed to estimate the 
frequency of prescription errors described in the present 
study methodology. We found that the dose of the drugs 
(6%), drug administration route (13%), frequency of dosage 
timing (1%), and length of treatment (42%) were not included 
in the prescriptions.
Potential drug–drug interactions and contraindications
According to the clinical literature, from the total number 
of elderly prescriptions (1,400) analyzed, it was found that 
4% of patients had the possibility of drug–drug interactions 
and 9% had potential contraindications. The most frequent 
drug–drug interaction was ASA–captopril (30 times). ASA 
was frequently prescribed in high doses (500 mg/day). 
An inadequate relationship was found between drug 
prescribed and diagnosis, indicating an error in the drug 
selection (3%).
Quality of prescriptions
When applying the PI as described in the Methods section, 
it was found that 53% of all prescriptions did not have a PI 
equal to zero and only 47% did. The level of association 
between the PI and the study variables was determined 
using Chi-squared test for a confidence interval (CI) of 
95%: (0–1.36)
The bivariate analysis of the PI quality showed that 
of all variables, the ones with statistical significance 
were the number of diagnoses per prescription (95% CI: 
0.1804–2.7424); p  0.000) and number of drugs (95% CI: 
0.3085–3.8029); p  0.000).
Logistic regression
A multivariate statistical analysis was conducted with the 
statistically significant variables. The results indicate that 
prescription quality (as determined by PI) depends on the 
number of prescribed drugs per prescription (p  0.000). 
The number of diagnoses was not statistically significant 
(p  0.05). Please see Table 1.
Discussion
The drug prescription pattern of the study population 
(elderly people aged 70 years and over) shows that 
some drugs like captopril and naproxen are used 
inappropriately in relation to the most frequent diseases. 
No high tendency towards polypharmacy (when five or 
more drugs are used concomitantly), possible drug–drug 
interactions, and contraindications were found. Very few 
patients were prescribed with five or more drugs per 
prescriptions.10
The two most frequent diseases in the study population 
were arterial hypertension (28.5%) and diabetes mellitus 
(14%), which are also the main causes of death in the 
Mexican general adult population. Nevertheless, the most 
prescribed drugs were captopril (463 times, 16.07%) and 
naproxen (298 times, 10.34%). Prescriptions including 
naproxen, in some cases, were not consistent with the patient 
diagnosis. Besides, naproxen is included in the Beers’s list 
of potentially inappropriate medications for the elderly.38 
As mentioned by Fick and colleagues.38 Toxic effects of 
medications and drug-related problems can have profound 
medical and safety consequences for older adults and 
affects the health care system economically. Thirty percent 
of hospital admissions in elderly patients may be linked to 
drug-related problems or toxic drug-related side effects.38 
Some risk factors related to nonsteroidal anti-inflammatory 
drugs (NSAIDs) were documented by Bateman and Kerr.39 
Serious gastrointestinal (GI) events occurred frequently in 
patients taking NSAIDs (naproxen) who had not experi-
enced any warning symptoms; it is important to identify 
factors that increase the risk of serious GI complication 
and to consider how the risk can be reduced. The risk of 
GI complication increases linearly with advanced age, 
a primary risk factor.39
Some studies have demonstrated that NSAIDs produced 
a decline in glomerular filtration rate (GFR) and that the 
decline in renal function has particular implications for the 
safe use of NSAIDs therapy in the elderly, since a decrease 
Table 1 Bivariate analysis and logistic regression results
Variables Bivariate analysis: 
Chi-squared test  
(95% CI) p  0.05
Multivariate 
analysis and logistic 
regression p  0.05
number of diagnoses 0.000 0.077
number of drugs 0.000 0.000
gender 0.343 –
Age 0.942 –
Abbreviation: CI, confidence interval.Clinical Interventions in Aging 2009:4 348
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in renal perfusion may place these individuals at increased 
risk of NSAIDs-induced acute renal impairment.40,41 In 
addition to hemodynamically mediated acute renal failure, 
other renal syndromes and side effects associated with 
NSAID use have been characterized. Cyclooxygenase 2 
(COX-2) is primarily an inducible enzyme, while COX-1 
is constitutively expressed in nearly all normal tissues, but 
is especially important in the gastrointestinal tract, kidneys, 
and platelets.40
In their study of the effects of celecoxib and naproxen 
on renal function in the elderly, Whelton and colleagues 
concluded that COX-2-specific inhibition in healthy elderly 
may spare renal hemodynamic function, although the effects 
on sodium excretion, as well as urinary prostaglandin E2, 
and 6-keto-prostaglandin F1α excretion, appear to be similar 
to those of nonspecific cyclooxygenase inhibitors such as 
naproxen.40
COX-2 inhibitors versus nonselective NSAIDs and their 
congestive heart failure outcomes in elderly patients were 
investigated by Mamdani and colleagues and others, and their 
findings suggest a higher risk of admission for congestive 
heart failure in users of rofecoxib (COX-2) and nonselective 
NSAIDs, but not relative to celecoxib, relative to non-NSAID 
controls.41–44
The drug prescription pattern suggests the need to 
establish rational drug therapy.
Most of the prescription errors (53%) in group 2 variables 
were due to omissions of dosage, administration route, and 
treatment length. Most of the general physicians in the pres-
ent study refused to comply with the EDL.
The EDL includes clear specifications for the rational 
use of each drug (patient age, dosage, administration route, 
treatment length, drug pharmaceutical presentation, drug time 
frequency, drug–drug interactions, and contraindications). 
Any one of the prescription errors mentioned above might not 
contribute to a dangerous health situation for elderly people, 
but can potentially worsen their condition.
Our results are similar to other studies that have reported 
inappropriate medication use in an elderly population.3,6,7
Prescription quality is poor (53%), being affected mainly 
by the number of drugs per patient. Due to the potential 
drug–drug interactions detected, it seems to us that no risk/
benefit relationship was established among concomitant drug 
regimens and diagnoses.
Even though the number of potential drug–drug interac-
tions is not high in the present study, it is important to point 
out that all of them were preventable.45 ASA–captopril (the 
effect of angiotensin-converting enzyme inhibitors may 
be blunted by ASA administration), allopurinol–captopril 
(a possible increased risk of Stevens–Johnson syndrome), 
ASA–furosemide (ASA blocks the diuretic effect of 
furosemide), metformin–metoprolol (β-blocker alters glucose 
metabolism). The combination of captopril–furosemide can 
be safe and effective, but (a) a few patients may feel dizzy 
or lightheaded within an hour of taking the first dose and 
acute hypotension can occur; (b) hyperkalemia is possible if 
potassium-sparing diuretics (eg, amiloride, spironolactone, 
triamterene) and/or potassium supplements are used concur-
rently; (c) hypokalemia may occur if potassium-depleting 
diuretics are used (furosemida); (d) severe renal deteriora-
tion and failure has been seen in patients with renal arterial 
stenosis.46
Four of the nine potential drug–drug interactions 
are associated with captopril: captopril–isosorbide 
(hyperkalemia), ASA–antiacids (antacids decreases salycilate 
seric concentrations), metformin–ranitidine (increases 
the risk of lactic acidosis), and enalapril–furosemide 
(hypotension and renal failure).28,34–36 Despite these indica-
tions, no clinical assessment was done. The risk/benefit 
rate of some drugs was assessed, and potential drug–drug 
interactions were identified based on written prescriptions 
and clinical literature.
We acknowledge that some of the combinations theo-
retically reported as undesirable (such as ASA–captopril) 
depending on the individual patient’s health status are fre-
quently used by physicians. Besides, additional information 
is needed on the timing of administration, laboratory tests, 
among other parameters.
General physicians should do much better if they pre-
scribe carefully for elderly and observe the EDL guidelines. 
As can be concluded for this particular group of elderly 
outpatients, most of the potential drug–drug interactions 
could be prevented by managing the prescription of antihy-
pertensive drugs and hypoglycemic agents.
The poor quality of prescriptions might be explained 
by data obtained from health care centers about physician 
professional’s profiles. The average age of doctors is 
28 years; they are very young and some have not completed 
their medical training, have very little experience and 
have not yet specialized in any medical sciences (general 
physicians).
The other problem in Mexico is the absence of community 
pharmacists; none of the health care centers has a phar-
macist. The person in charge of the pharmacy is generally 
not a health professional (has not a bachelor degree in 
pharmacy) and has less than a ninth degree level of education. Clinical Interventions in Aging 2009:4 349
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In the United States and the United Kingdom, professional 
pharmacists have made great contributions to improve 
prescribing in the ambulatory elderly population.47,48
Despite the substantial commitment of resources from 
the local Mexican government and others to promote and 
guarantee the access to drugs to the elderly and needy 
population, no ongoing information exists on the degree to 
which the Mexican elderly population is using the broad 
range of medications available, including prescription and 
over-the-counter drugs.
The prevention and recognition of drug-related problems 
in elderly patients and other vulnerable populations is one 
of the principal quality and safety issues for this decade.38 
Drug–drug interactions are a preventable cause of morbidity 
and mortality, yet their consequences in the community are 
not well characterized.45 Mexico City is not an exception to 
that statement.
The limitations of our study are the reliability of data 
obtained from prescriptions, which could lead to some 
measure of bias in our results. No medical records were 
revised. We used only prescriptions issued during the study 
period. The lack of information on other products used to 
treat the diseases presented (eg, use of over-the-counter 
drugs and herbal products), which might interact with the 
prescribed drugs and the elimination of prescriptions that 
were not clearly written could bias our results as a main 
source of potential prescription errors. As well as the lack of 
confirmation of the health conditions for which prescriptions 
were written, the absence of information on other health 
conditions present and health care outcomes could also bias 
our results.
study limitations
We evaluated potential medication prescription patterns and 
errors in the elderly adult population. No clinical patient 
assessment was done; only prescriptions were evaluated. 
As a retrospective study, its limitations are inherent to the 
study design. Evaluation of the prescription errors were based 
on clinical literature, the Mexican EDL, and the updated 
Beer’s guidelines.
Conclusions
A high number of potential prescription errors were 
found, mainly due to omissions. The drug prescription 
pattern of the study population is mainly constituted by 
12 drugs. Our results indicate that prescription quality 
depends on the number of prescribed drugs per prescription 
(p  0.000).
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